Last reviewed 2026-04-20 · How we verify

Keveyis (DICHLORPHENAMIDE)

Keveyis works by inhibiting the enzyme carbonic anhydrase, which is involved in the production of aqueous humor in the eye.

Keveyis (Dichlorphenamide) is a small molecule carbonic anhydrase inhibitor developed by an unspecified original developer and currently owned by Xeris. It targets carbonic anhydrase 1 to treat various forms of glaucoma, including angle-closure, open-angle, and secondary glaucoma. Approved by the FDA in 1958, Keveyis is an off-patent medication with multiple generic manufacturers. As a carbonic anhydrase inhibitor, it works by reducing the production of aqueous humor in the eye, thereby lowering intraocular pressure. Keveyis is a valuable treatment option for patients with glaucoma, but its commercial status and pharmacokinetic properties are not well-documented.

At a glance

Mechanism of action

Dichlorphenamide is carbonic anhydrase inhibitor. However, the precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with primary periodic paralysis is unknown.

Approved indications

• Angle-closure glaucoma
• Open-angle glaucoma
• Secondary glaucoma

Common side effects

• Paresthesia
• Cognitive disorder
• Dysgeusia
• Confusional state
• Headache
• Diarrhea
• Arthralgia
• Rash
• Pruritus
• Dizziness
• Lethargy
• Hypoesthesia

Key clinical trials

• Hyper- and Hypokalemic Periodic Paralysis Study (PHASE3)
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.